Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,009.42
    -62.21 (-1.23%)
     

  • Dow

    37,823.89
    -637.03 (-1.66%)
     

  • Nasdaq

    15,484.50
    -228.25 (-1.45%)
     

  • Bitcoin USD

    63,731.83
    -2,312.44 (-3.50%)
     

  • CMC Crypto 200

    1,372.58
    -9.99 (-0.72%)
     

  • FTSE 100

    8,049.15
    +8.77 (+0.11%)
     

  • Gold

    2,332.90
    -5.50 (-0.24%)
     

  • Crude Oil

    82.46
    -0.35 (-0.42%)
     

  • 10-Yr Bond

    4.7230
    +0.0710 (+1.53%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Alnylam Stock Up More Than 61% YTD on Pipeline Progress

Zacks Equity Research

Shares of Alnylam Inc. ALNY have soared 61.2% year to date compared with the industry’s growth of 8.8%.  Let us look at some of the factors backing the surge.

In November, the FDA approved givosiran injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). The approval came three months before the PDUFA date of Feb 20, 2020. Givosiran injection will be marketed by the trade name of Givlaari. This is the second RNA interference (RNAi) therapeutic of Alnylam approved by the FDA in the last sixteen months. The drug’s approval was based on positive results from the phase III ENVISION study, which showed that AHP patients treated with the same experienced 70% lesser porphyria attacks compared to placebo.

The company expects to achieve regulatory approval from the European Medicines Agency (EMA) for Givlaari (givosiran) in early 2020 for the treatment of AHP. It also plans to execute on U.S. and EU commercial launches throughout 2020.

Alnylam’s first-of-its-kind RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, Onpattro, is witnessing strong uptake since launch.

ADVERTISEMENT

The company is also evaluating several other candidates. A few significant ones include vutrisiran (ALN-AAT02), the first investigational RNAi therapeutic targeting AAT with Alnylam’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology. During the third quarter of 2019, the company continued enrollment in the HELIOS-A phase III study on vutrisiran (ALN-TTRsc02) for the treatment of hATTR amyloidosis with polyneuropathy.  It  expects to complete enrollment in the study in early 2020. In November, Alnylam initiated the HELIOS-B phase III study of vutrisiran.

Other candidates include  ALN-CC5 in phase I/II being evaluated to treat complement-mediated diseases, cemdisiran in phase II to treat complement-mediated diseases and lumasiran in phase I/II to treat  Primary Hyperoxaluria Type 1 (PH1).

In December, the company announced positive top-line results from the phase III study of lumasiran. The ILLUMINATE-A study met its primary efficacy endpoint and all tested secondary endpoints.

In April, Alnylam and Regeneron Pharmaceuticals REGN extended their collaboration agreement. Both companies will work together to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The companies plan to advance programs directed to 30 targets. Other candidates also might be introduced into clinical developments during the initial five-year discovery period, which may extend.

 

Alnylam Pharmaceuticals, Inc. Price

 

Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote

Zacks Rank & Stocks to Consider

Alnylam is a Zacks Rank #3 (Hold) stock, currently.

A few better-ranked stocks in the biotech sector are Alkermes Plc. ALKS and Innoviva Inc. INVA, both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Alkermes’’s earnings per share estimates have increased from 36 cents to 52 cents for 2019 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters by 236.80%, on average.

Innoviva’s earnings per share estimates have increased from $1.71 to $2.03 for 2019 and from $1.07 to $1.34 for 2020 in the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
Alkermes plc (ALKS) : Free Stock Analysis Report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research